• 1
    Quick AJ. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 734.
  • 2
    Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 3): 204S33S. Erratum in: Chest 2005; 127: 415–6. Dosage error in text.
  • 3
    Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49: 23844.
  • 4
    WHO. Expert Committee on Biological Standardisation. 33rd Report. WHO Technical Report Series 1983; 687: 81105.
  • 5
    Van Den Besselaar AMHP, Poller L, Tripodi A. Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy (1999). WHO Technical Report Series 1999; 889: 6493.
  • 6
    Tripodi A, Breukink-Engbers WGM, Van Den Besselaar AMHP. Oral anticoagulant monitoring by laboratory or near patient testing: what a clinician should be aware of. Sem Vasc Med 2003; 3: 24354.
  • 7
    Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transaction of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 6469.
  • 8
    Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 86471.
  • 9
    Hedner U, Erhardtsen E. Hemostatic disorders in liver disease. In: SchiffER, SorrellMF, MaddreyWC, eds. Diseases of the Liver, Philadelphia: Lippincott Williams and Wilkins, 2003: 62535.
  • 10
    White GC, Marder VJ, Colman RV, Hirsh J. Approach to the bleeding patient. In: ColmanRW, HirshJ, MarderVJ, SalzmanEW, eds. Hemostasis and Thrombosis. Basic principles and clinical practice, 3rd edn. JB Lippincott Company: Philadelphia, 1994: 9658.
  • 11
    Bauer KA. Inherited and acquired hypercoagulable state. In: Lo ScalzoJ, SchaferAJ, eds. Thrombosis and Hemorrhage, 3rd edn. Lippincott Williams and Wilkins: Philadelphia, 2003: 64884.
  • 12
    Carmassi F, De Negri F, Morale M, et al. Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis. Lancet 1997; 349: 1069.
  • 13
    Aurousseau MH, D’Angeli JL, Josso F. Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis 1981; 10: 1047.
  • 14
    Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999; 94: 256974.
  • 15
    Montalto P, Vlachogiannakos J, Cox DJ, et al. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002; 37: 46370.
  • 16
    Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 5538.
  • 17
    Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44: 4405.
  • 18
    Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 10916.
  • 19
    Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 47436.
  • 20
    Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002; 359: 478.
  • 21
    Schemmer P, Decker F, Dei-Anane G, et al. The vital threat of an upper gastrointestinal bleeding: Risk factor analysis of 121 consecutive patients. World J Gastroenterol 2006; 12: 3597601.
  • 22
    Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 38893.
  • 23
    Dillon JF, Simpson KJ, Hayes PC. Liver biopsy bleeding time: an unpredictable event. J Gastroenterol Hepatol 1994; 9: 26971.
  • 24
    Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 141325.
  • 25
    Boks AL, Brommer EJ, Schalm SW, et al. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6: 7986.
  • 26
    Diaz LK, Teruya J. Liver biopsy. New Engl J Med 2001; 344: 2030.
  • 27
    Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40: 4848.
  • 28
    Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67: 13845.
  • 29
    McGill DB, Rakela J, Zinsmeister AR, et al. A 21 year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396400.
  • 30
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. New Engl J Med 2001; 344: 495500.
  • 31
    Jacobs WH, Goldberg SB. Statement on outpatient percutaneous liver biopsy. Dig Dis Sci 1989; 34: 3223.
  • 32
    Sue M, Caldwell SH, Dickson RC, et al. Variation between centres in technique and guidelines for liver biopsy. Liver 1996; 16: 26770.
  • 33
    Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 103946.
  • 34
    Lisman T, Bongers T, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 5361.
  • 35
    Hu K-Q, Yu AS, Tiyyagura L, et al. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 15816.
    Direct Link:
  • 36
    Bosch J, Thabut D, Bendtsen F, et al. European Study Group on rFVIIa in UGI Haemorrhage Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 112330.
  • 37
    Lodge JP, Jonas S, Jones RM, et al. rFVIIa OLT Study Group Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 9739.
  • 38
    Planinsic RM, Van Der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11: 895900.
  • 39
    Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986; 90: 123240.
  • 40
    Castaneda B, Morales J, Lionetti R, et al. Effects of blood volume restitution following portal hypertensive-bleeding in anesthetized cirrhotic rats. Hepatology 2001; 33: 8215.
  • 41
    AuBuchon JP. Meeting transfusion safety expectations. Ann Intern Med 2005; 143: 5378.
  • 42
    Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 3458.
  • 43
    Bauer KA. New anticoagulants: anti IIa vs anti Xa. Is one better? J Thromb Thrombolysis 2006; 21: 6772.
  • 44
    Wiesner R, Edwards E, Freeman R, et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor liver. Gastroenterology 2003; 124: 916.
  • 45
    Institute of Medicine Committee on Organ Procurement and Transplantation Policy. Organ Procurement and Transplantation: assessing current policies and the potential impact of the DHHS final rule. Washington, DC: National Academy Press 1999: 129.
  • 46
    United Network for Organ Sharing. (accessed December 20, 2005).
  • 47
    Trotter JF, Brimhall B, Arjal R. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10: 9951000.
  • 48
    Kenison J, Arjal R, Smith A, et al. Inter-laboratory variation in INR leads to clinically relevant changes in MELD score: survey of US clinical laboratories. Am J Transpl 2006; 6(Suppl. 2): 333.
  • 49
    Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio. Hepatology 1996; 24: 13924.
  • 50
    Kovacs MJ, Wong A, MacKinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Hemostas 1994; 71: 72730.
  • 51
    Denson KW, Reed SV, Haddon ME, et al. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res 1999; 94: 25561.
  • 52
    Mancuso A, Fung K, Cox D, et al. Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood. Blood Coagul and Fibrinolysis 2003; 14: 2116.
  • 53
    Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007 (in press).